Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Stocks to buy : Jio Financial, SBI Card and Canara Bank on investors' radar
17/04/2025
Wobbly stock market puts a dent in mutual fund SIPs in 2025
17/04/2025
PEs have more comfort with big bets in India : Joseph Bae, KKR
17/04/2025
Hospital stocks gain on safe-haven buying
17/04/2025
Federal Reserve can wait on any rate moves : Powell
17/04/2025
US economy slowing in Q1, can wait for greater clarity : U.S. Federal Reserve Chair Jerome Powell
16/04/2025
